Please ensure Javascript is enabled for purposes of website accessibility

Fluidigm's Saliva Coronavirus Test Being Run by 2 Certified Labs

By Brian Orelli, PhD – Sep 16, 2020 at 4:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The labs are each processing three-thousand tests per day.

After receiving an emergency use authorization from the Food and Drug Administration (FDA) last month, Fluidigm (FLDM -3.25%) reported that its saliva-based test for the novel coronavirus that causes COVID-19 is being run at two Clinical Laboratory Improvement Amendments (CLIA) certified labs. The tests, which go by the unweildly name, Advanta Dx SARS-CoV-2 RT-PCR Assay, are being processed by ImmunoGenomics, based in metropolitan Houston, and Vero Diagnostics, of Research Triangle Park, North Carolina.

These aren't the first labs to start testing Fluidigm's saliva-based test. A Fluidigm representative told The Motley Fool, "We highlighted ImmunoGenomics and Vero Diagnostics because they are representative of the small- and medium-sized labs that are running our test. In addition, large public health organizations and major academic centers are adopting our saliva-based test."

Gloved hand taking a mouth swab.

Image source: Getty Images.

Unlike most coronavirus tests, the Advanta Dx SARS-CoV-2 RT-PCR Assay doesn't require a swab to be stuck up the patient's nose, which many patients have reported as uncomfortable. Instead, a little saliva is all that's required for the machine to determine if the novel coronavirus is present. The data package submitted to the FDA showed 100% agreement between the saliva test and the nasal test.

The test runs on Fluidigm's Biomark HD system, so any CLIA certified lab with the machine should be able to run the test. The system can run up to 6,000 samples per day per system, although both ImmunoGenomics and Vero Diagnostics are currently only running about 3,000 of Fluidigm's saliva tests per day.

Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Fluidigm Corporation Stock Quote
Fluidigm Corporation
FLDM
$1.19 (-3.25%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.